Anhui Wanbang Pharmaceutical Technology Co., Ltd. is a China-based contract research organization that provides comprehensive, one-stop research and development outsourcing services across the pharmaceutical product lifecycle. Founded in 2006 and headquartered in Hefei, Anhui Province, the company primarily serves pharmaceutical manufacturers, biotechnology enterprises, medical device developers, and scientific research institutions throughout mainland China. The company organizes its operations into clinical research services, pharmaceutical chemistry and formulation research, and technology transfer solutions. Its core offerings include bioequivalence and clinical pharmacology studies; Phase I through Phase III clinical trial design, site selection, and trial monitoring; Site Management Organization services; biological sample analysis and pharmacokinetics testing; clinical data management and biostatistical analysis; independent third-party clinical audits; generic drug research and consistency evaluation; formulation development, chemical synthesis, and analytical testing; as well as regulatory filing, drug registration dossier compilation, and technology transfer services. In recent strategic corporate developments, the company completed its initial public offering on the Shenzhen Stock Exchange ChiNext board in September 2023 under ticker 301520. In June 2026, the company completed the acquisition of a 75.52 percent controlling stake in Anhui Saidesheng Pharmaceutical Technology Co., Ltd. for approximately RMB 302 million to expand its full-chain clinical research capabilities in innovative drugs across oncology, respiratory, and gastroenterology indications, while incorporating specialized third-party auditing capabilities via Saidesheng subsidiary Beijing Dinghui Sichuang. The company has also continued to broaden its business scope beyond traditional generic drug bioequivalence into complex generics, biosimilars, medical device testing, and integrated healthcare technical services.